Currently licensed medications have efficacy to control aspects related to inflammation, but have been unable to modify pure progression.
Experimental work has provided robust evidence of the immunomodulatory and neuroprotective properties that cannabinoids exert in animal models of multiple sclerosis.
Through activation of the CB2 receptor, cannabinoids modulate peripheral blood lymphocytes, interfere with migration across the blood-brain barrier and control microglial/macrophage activation. CB1 receptors present in neural cells have a fundamental role in direct neuroprotection against several insults, mainly excitotoxicity.
In multiple sclerosis, several reports have documented the disturbance of the endocannabinoid system.
Considering the actions demonstrated experimentally, cannabinoids might be promising agents to target the main aspects of the human disease.